Print
Email
Print Edition StoriesWednesday, April 29, 2009
Mass. Life Sciences Board gives out first Accelerator loans
By Marc Songini
MHT's Efrain Viscarolasaga: How social networking is changing business
MHT's Marc Songini: RI plans launch of cord blood center
The Massachusetts Life Sciences Center has picked the first seven recipients of its much-anticipated Accelerator Program loans.
The winners were announced today by the MLSC, a quasi-public agency tasked with overseeing the state’s $1 billion Life Sciences Initiative. The Accelerator program provides $3.4 million to life sciences firms in the state. Each company is eligible for as much as half a million dollars to support research and development, manufacturing and sales.
There were 88 applicants, according to a statement by the MLSC. Each applicant faced peer review and evaluation by the center’s Scientific Advisory Board, as well as an investment committee.
The seven companies that will receive loans are:
Boston-based Eutropics Pharmaceuticals, an oncology drug company working on chemicals to treat myeloma, lymphoma, leukemia, and other cancers.
Good Start Genetics, a Boston-based molecular diagnostics company working to create a low-cost, pre-pregnancy test for 50 genetic disorders. This would replace single disorder tests.
InVivo Therapeutics Corp., a Cambridge biotech working on implants for spinal cord injuries.
Pluromed, a Woburn-based startup developing injectable plugs to improve cardio-thoracic surgery procedures. When injected, the plugs solidify and block off blood flow so surgeons can more easily operate. When cooled, the plugs liquefy and dissolve.
Marlborough-based Spectra Analysis, which supplies molecular spectroscopy systems and applications for chromatography processes.
Wadsworth Technologies, based in Westborough, which develops medical devices that close wounds. Its lead product is the Dermaloc Wound Closure System, and is currently in clinical testing.
Watertown-based Wolfe Laboratories Inc., which offers assay, formulation and process development and other services to the biotechnology and pharmaceutical industries.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
